Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts

Información del proyecto

IMMUcan

Identificador del acuerdo de subvención: 821558

DOI

10.3030/821558

Fecha de la firma de la CE 23 Abril 2019

Fecha de inicio 1 Marzo 2019

Fecha de finalización 30 Junio 2026

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 37 187 251,00

Aportación de la UE

€ 17 830 000,00

Coordinado por

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
Belgium

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Documents, reports (3)

Independent boards (EAB and SAB) up and constituted

Report on the composition of these boards.

Policy for third party access and use of project results

On month 1, it will be an agreement on the key principles regarding 3rd party access allowing to discuss contract with non-EORTC groups. The full policy will be available by month 6.

Leaflet in lay language

Leaflet explaining the project in lay language.

Other (1)

First newsletter circulated

First newsletter

Publicaciones

Conference proceedings (10)

Abstract 176P Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study

Autores: A. Joaquin Garcia, J. Krawczyk, M. Rediti, K. Gogolewski, M. Możejko, S. Tissot, S. Rusakiewicz, L. Despland, M. Morfouace, R. Liechti, F. Marzetta, X. Wang, D. Vincent, J-C. Goeminne, J. Oliveira, H.S. Hong, M. Cesaroni, C. Sotiriou, E. Szczurek, L. Buisseret
Publicado en: Immuno-Oncology and Technology, 2023
Editor: Elsevier
DOI: 10.1016/j.iotech.2023.100635

Abstract 179P Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort

Autores: M. Rediti, A. Joaquin Garcia, S. Tissot, S. Rusakiewicz, L. Despland, M. Morfouace, R. Liechti, F. Marzetta, J. Oliveira, J-C. Goeminne, A. Capela Marques, L. Greillier, X. Wang, D. Vincent, H.S. Hong, M. Cesaroni, C. Sotiriou, L. Buisseret
Publicado en: Immuno-Oncology and Technology, 2023
Editor: Elsevier
DOI: 10.1016/j.iotech.2023.100638

Abstract 186P Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: An EORTC IMMUcan sub-project

Autores: A. Van Der Elst, D. Herrero Saboya, L. Michon, M. Morfouace, R. Liechti, D. Schulz, P. Devanand, R. Galot, A. Essabar, V. Pancaldi, J. Merlevede, H.S. Hong, L. Martignetti, C
Publicado en: Immuno-Oncology and Technology, 2023
Editor: Elsevier
DOI: 10.1016/j.iotech.2023.100645

Abstract 199P Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium

Autores: N. Eling, J. Dorier, S. Rusakiewicz, S. Tissot, P. Devanand, M. Daniel, S. Déglise, B. Palau Fernandez, J. Windhager, M. Możejko, K. Gogolewski, J. Krawczyk, A. Essabbar, V. Pancaldi, E. Szczurek, M. Morfouace, H.S. Hong, R. Liechti, B. Bodenmiller, D. Schulz
Publicado en: Immuno-Oncology and Technology, 2023
Editor: Elsevier
DOI: 10.1016/j.iotech.2023.100675

Abstract 195P IMMUcan: Toward a better understanding of the tumor microenvironment to inform precision oncology approaches

Autores: M. Morfouace, L. Buisseret, B. Besse, J-P. Machiels, C. Sotiriou, M-S. Robert, D. Schaer, S. Rusakiewicz, D. Schulz, B. Fournier, H.S. Hong, R. Liechti
Publicado en: Immuno-Oncology and Technology, 2023
Editor: Elsevier
DOI: 10.1016/j.iotech.2023.100654

Abstract 202P Discovery of immunological cellular neighborhoods from protein markers in spatial tumor data

Autores: M. Możejko, K. Gogolewski, D. Schulz, N. Eling, J. Krawczyk, A. Możwiłło, M. Daniel, E. Staub, M. Mourface, H.S. Hong, B. Bodenmiller, E. Szczurek
Publicado en: Immuno-Oncology and Technology, 2023
Editor: Elsevier
DOI: 10.1016/j.iotech.2023.100678

Abstract 2266P IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort

Autores: M. Morfouace, D. Schulz, N. Eling, F. Marzetta, C. Loizides, S. Rusakiewicz, R. Liechti, H.S. Hong, M-S. Robert, P. Bironzo, T. Cufer, K. Oselin, N. Cloarec, J. Oliveira, B. Bodenmiller, B. Besse,
Publicado en: Annals of Oncology, 2023
Editor: Elsevier
DOI: 10.1016/j.annonc.2023.09.1294

Abstract 4522: Pathologic complete response rate across triple negative breast cancer subtypes in the IMMUcan study

Autores: Andrea Joaquin Garcia; Mattia Rediti; Abdelkader Benyagoub; Stéphanie Tissot; Sylvie Rusakiewicz; Robin Liechti; Flavia Marzetta; Nicolas Penel; Julio Oliveira; Jean-Charles Goeminne; Pierre Fournel; Andreia Capela; Xiaoxiao Wang; Delphine Vincent; Françoise Rothe; Marie Morfouace; Henoch Hong; Donald Jackson; Christos Sotiriou; Laurence Buisseret
Publicado en: Immuno-Oncology and Technology, 2023
Editor: Elsevier
DOI: 10.1158/1538-7445.am2023-4522

Abstract 2274P: Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study

Autores: C. Esposito, A. Joaquin Garcia, M. Rediti, N. Penel, J. Oliveira, J-C. Goeminne, P. Fournel, A. Capela Marques, M. Morfouace, L. Buisseret, H.S. Hong, C. Maussion
Publicado en: Annals of Oncology, 2023
Editor: Elsevier
DOI: 10.1016/j.annonc.2023.09.1302

Abstract 1P Integrated data analysis within IMMUcan identifies prognostic features of early NSCLC

Autores: D. Schulz, M. Morfouace, N. Eling, M. Daniel, S. Déglise, B. Palau Fernandez, J. Windhager, S. Rusakiewicz, S. Tissot, T. Trefzer, J. Merlevede, F. Marzetta, R. Liechti, H.S. Hong, T. Cufer, P. Bironzo, A-M.C. Dingemans, B. Besse, B. Bodenmiller
Publicado en: Immuno-Oncology and Technology, 2023
Editor: Elsevier
DOI: 10.1016/j.iotech.2023.100473

Peer reviewed articles (3)

Yes, IMMUcan! Unraveling the human tumor microenvironment

Autores: Henoch Hong, Robin Liechti, Marie Morfouace
Publicado en: Immuno-Oncology Insights, Edición 2021; 2(5),, 2021, Página(s) 301–309, ISSN 2059-7800
Editor: BioInsights Publishing Ltd
DOI: 10.18609/ioi.2021.038

CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy.

Autores: Franken A, Bila M, Mechels A, Kint S, Van Dessel J, Pomella V, Vanuytven S, Philips G, Bricard O, Xiong J, Boeckx B, Hatse S, Van Brussel T, Schepers R, Van Aerde C, Geurs S, Vandecaveye V, Hauben E, Vander Poorten V, Verbandt S, Vandereyken K, Qian J, Tejpar S, Voet T, Clement PM, Lambrechts D.
Publicado en: Immunity, 2024, ISSN 1097-4180
Editor: Elsevier
DOI: 10.1016/j.immuni.2024.02.007

Meta-analysis of human cancer single cell RNA-seq datasets using the IMMUcan database.

Autores: Jordi Camps; Floriane Noël; Robin Liechti; Lucile Massenet-Regad; Sidwell Rigade; Lou Götz; Caroline Hoffmann; Elise Amblard; Melissa Saichi; Mahmoud M. Ibrahim; Jack Pollard; Jasna Medvedovic; Helge G. Roider; Vassili Soumelis
Publicado en: Cancer Research, 2023, ISSN 1538-7445
Editor: AACR
DOI: 10.1158/0008-5472.can-22-0074